ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO776

Tandem Plasmapheresis on Continuous Renal Replacement Therapy in Pediatrics

Session Information

  • Pediatric CKD
    November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1700 Pediatric Nephrology


  • Tufan pekkucuksen, Naile, University of FLorida, Gainesville, Florida, United States
  • Sigler, Katharine, Texas Children's Hospital, Houston, Texas, United States
  • Akcan Arikan, Ayse, Baylor College of Medicine, Houston, Texas, United States
  • Srivaths, Poyyapakkam, Baylor College of Medicine, Houston, Texas, United States

Plasmapheresis (TPE) has been used successfully to reduce concentration of pathogenic antibodies, immune complexes, cryoglobulins and lipoproteins Continuous renal replacement therapy (CRRT) is the treatment modality for acute kidney injury, fluid overload and electrolyte and metabolic imbalance for unstable patients. Reported experience about simultaneous use of TPE and CRRT (referred to as tandem TPE) in pediatric (ped) patients (pts) is scarce.


We describe tandem TPE experience from our institution. Retrospectively reviewed ped pts receiving tandem TPE from 2013 to 2016. Centrifugal based TPE was performed, all CRRT patients received hemodiafiltration at minimum starting dose of 2000 ml/1.73m2/hour with regional citrate anticoagulation. For tandem TPE apheresis lines were “Y”ed in the circuit in parallel without using additional anticoagulation.


63 pts received tandem TPE, for a total 378 of TPE procedures on 1676 days of CRRT. Age ranged from newborn to 19 years old, weights ranged from 2.31 to 112.3 kg (17 pts were <10 kg and < 1 year old). Most common indications were coagulopathy and hepatic encephalopathy caused by acute liver failure (20 pts), thrombocytopenia associated multi-organ failure (TAMOF) (19 pts) and thrombotic microangiopathy (5pts). Median number of TPE session per pt was 5 (IQR:3;7). Median number of CRRT days was 12 (6; 37). All treatments were completed successfully. 57 (90%) patients had hypocalcemia and 59 (94%) patients had hypercalcemia at least one time during the treatments. 27 (43%) patients had citrate accumulation (defined by plasma total calcium/ionized calcium >2.5 mmol) during the treatments. All episodes were asymptomatic. Case mortality rate was 40%. Time to CRRT and TPE initiation was longer in non-survivors (NoS) vs survivors (3 d (1,9) vs 1 (1,2) & 4 d (2,13) vs. 2 (1,3) TPE) (p=0.02). PRISM score at ICU admission of NoS is significantly higher (p=0.031).


Tandem TPE treatment during CRRT can be effectively used in pediatric pts over a broad age and weight range. Complications including hypocalcemia are common though pts remained asymptomatic. Complex treatments need to be planned carefully with interdisciplinary team to address indications, technicalities and complications.